Our pipeline

research
compound
target/mechanism
indication
preclinical
clinical
Phase I
Phase II
Phase III
tnk01
tnk01xx
unpublished
solid tumor
tnk02
tnk02xx
unpublished
solid tumor
tnk01
unpublished
unpublished
solid tumor
preclinical research and development
clinical declaration
Phase I
Phase II
Phase III
tnk02
unpublished
unpublished
solid tumor
preclinical research and development
clinical declaration
Phase I
Phase II
Phase III

Our focuses

"synthetic lethal"

jpg" 0c1_ph1.jpg

innovative achievements

focusing on the development of drug resistant targets, tongnuokang has independently built a series of research platforms based on the combination of artificial intelligence (ai) and multi omics technology (omics). tumor therapy based on synthetic lethal therapy can accurately target cancer cells, and can also accurately screen patients according to their cancer cell gene mutations. in the future, synthetic lethal therapy will play a huge role in tumor precise therapy.